# Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System

> **NCT00647842** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 120 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay
- **DRUG:** Fentanyl Transdermal System 25 mcg/h

## Key facts

- **NCT ID:** NCT00647842
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00647842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00647842, "Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00647842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*